Personalis, Inc.
Personalis, Inc. (Nasdaq: PSNL) develops and sells genomic testing services for cancer care, pharmaceutical research and other sequencing applications. For cancer patients, its NeXT Personal Dx liquid biopsy test monitors minimal residual disease and recurrence, while NeXT Dx profiles tumors to help physicians assess… From the company’s description.
Over the twelve months to Sep 30, 2026, Personalis, Inc. reported revenue of $80.77M, up 16.9% from a year earlier, and a net loss of $119.33M. Its operating margin was −156.7%, and operations used $97.57M in cash. In fiscal 2025, it reported revenue of $69.65M, down 17.7% from fiscal 2024, and a net loss of $81.27M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Personalis, Inc. does
In the company’s own words
Personalis, Inc. (Nasdaq: PSNL) develops and sells genomic testing services for cancer care, pharmaceutical research and other sequencing applications. For cancer patients, its NeXT Personal Dx liquid biopsy test monitors minimal residual disease and recurrence, while NeXT Dx profiles tumors to help physicians assess treatment options and clinical trials. Pharmaceutical and biotechnology companies use NeXT Personal for clinical trials and therapy development, and ImmunoID NeXT to study tumors and identify biomarkers. Personalis also provides whole-exome sequencing to diagnostic companies and whole-genome sequencing for population initiatives. Customers include pharmaceutical and biopharmaceutical companies, diagnostic companies, universities, nonprofits, government entities and cancer patients; distribution includes direct sales and a co-commercialization partnership with Tempus. The company manages its business as one operating segment focused on advanced cancer genomic testing and related services. It performs testing at a CLIA-certified, CAP-accredited laboratory in a 100,000-square-foot facility. In 2025, the United States accounted for 90% of revenue, Europe for 9% and other regions for 1%.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- FREMONT, CA
- Fiscal year end
- December
- CIK
- 1527753
- SIC
- 8071
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Personalis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Personalis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Personalis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Personalis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Personalis, Inc.'s last four quarterly filings that the numbers alone won't show?”